These results suggested that the PCSK9-CAP1-PKCδ/Syk pathway may be a viable target for developing new therapeutics for dyslipidemia, atherosclerotic cardiovascular diseases, and inflammation-based diseases. Here, CAP1 is linked to metabolic syndrome.